Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R33 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Phase II (R33) grant applications to facilitate early-stage T1 translation (bench-to-bedside) of discoveries from basic and applied research in aging into novel therapeutics for the prevention and treatment of clinical conditions related to aging or multiple chronic conditions in older people (e.g., sarcopenia, hearth failure with preserved ejection fraction (HFePF), immunosenescence, pulmonary fibrosis, metabolic syndrome, chronic kidney disease). This includes the development of pharmacological strategies such as new classes of compounds (e.g., senolytics, anti-inflammatory agents, modulators of proteostasis and autophagy), natural products (or their derivatives, mimics, and synthetic equivalents), biologics, stem/progenitor cell-based therapies, and the repurposing of Food and Drug Administration (FDA)-approved drugs. Applications submitted in response to this FOA may involve novel treatment targets and/or innovative approaches for engaging known targets.

The R33 mechanism is intended to provide milestone-driven support (up to 5 years) for innovative exploratory and developmental research activities originally initiated under the R21 mechanism. Awardees from NIA's R21 T1 translational aging research program are encouraged to apply to this FOA to expand upon the translation of their candidate pharmacological interventions from prior studies. Other applicants with sufficient and strong preliminary/proof-of-concept data (equivalent to that achievable under a R21) for a novel drug target, new compound(s), or for a potential new clinical indication for an FDA-approved drug for age-related conditions are also eligible to apply to this FOA. The scope of early-stage T1 translational research activities to be conducted under the R33 is expected to vary with the stage of translation of the candidate therapeutic. Nevertheless, the R33 support should advance the experimental intervention closer to human testing (if warranted).

The development of non-pharmacological interventions is considered outside the scope of this FOA.

Applications that focus on Alzheimer's disease or its related dementias are outside the scope of this announcement.

Companion FOA: PAR-19-305 R21/R33 Phased Innovation Award


  • Letter of Intent Due Date(s): 30 days before the application due date
  • R33 Due Dates: Feb. 16, Jun. 16, Oct. 16

PAR-19-304 Expiration Date July 17, 2022

Agency Website



Amount Description

Application budgets are limited to $300,000 in direct costs per year.

The scope of the proposed project should determine the project period, which may not exceed 5 years.

Funding Type





Medical - Translational

External Deadline

June 16, 2022